Casgevy Outlook: Morgan Stanley’s Take on CRISPR Therapeutics
Morgan Stanley upgraded CRISPR Therapeutics to Equal Weight, $60 target (~21% upside), sees Casgevy growth but mixed valuation views.
/ 1651 items
#XY↓
Humacyte Shares Slide on Stock Sale Despite Positive Dialysis Trial Data
Humacyte shares dropped following a $50M stock offering announcement. The move comes even as the company reported strong interim Phase 3 data for its ATEV in female dialysis access patients.
Chardan Slaps “Buy” Rating on CAMP4 Therapeutics – $6.50 Price Target Signals 60%+ Upside
Its new gene-boosting drug shows promise for rare brain disorders with no treatments yet.
B. Riley Sees Multi-Billion Dollar Potential in Elicio’s mKRAS Vaccine
B. Riley sees Elicio as a strong Buy; mKRAS cancer vaccine data in June could be a major stock catalyst.
Clover Health Triumphs in Court – Massive 4.5-Star Medicare Rating Upgrade
Clover Health got its Medicare rating raised to 4.5 stars, boosting future government bonus payments from 2027.
Barclays Predicts Oscar Health Will Benefit Most from ACA Boom
Barclays raised Oscar Health rating, sees higher price target as ACA growth and pricing gains boost future profits.